STABL — Stayble Therapeutics AB Income Statement
0.000.00%
Last trade - 00:00- SEK14.29m
- SEK9.49m
Annual income statement for Stayble Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | -10.5 |
| Selling / General / Administrative Expenses | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 14.9 | 12.1 | 24.8 | 24 | 12.8 |
| Operating Profit | -14.9 | -12.1 | -24.8 | -24 | -12.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.5 | -12.1 | -24.5 | -23.7 | -12.4 |
| Net Income After Taxes | -15.5 | -12.1 | -24.5 | -23.7 | -12.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.5 | -12.1 | -24.5 | -23.7 | -12.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.5 | -12.1 | -24.5 | -23.7 | -12.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.74 | -0.85 | -1.72 | -0.748 | -0.284 |
| Dividends per Share |